April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Characterization of SSRI Action in the Retina
Author Affiliations & Notes
  • J. W. Stoddard
    Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon
  • P. Francis
    Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon
  • Footnotes
    Commercial Relationships  J.W. Stoddard, None; P. Francis, None.
  • Footnotes
    Support  Foundation Fighting Blindness, Research to Prevent Blindness (USA)
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 3321. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. W. Stoddard, P. Francis; Characterization of SSRI Action in the Retina. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3321.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Brain-derived neurotrophic factor (BDNF) is a growth factor implicated in the survival and function of neurons. Multiple investigations have demonstrated the ability of BDNF to rescue photoreceptors from degenerating in animal models of age-related macular degeneration and inherited retinal disease. Selective serotonin reuptake inhibitors (SSRIs) act to increase the amount of serotonin in the extracellular space around neurons. Recent evidence suggests SSRI antidepressants mediate their beneficial effects in part by elevating BDNF expression in the adult brain. We hypothesize that SSRIs act in the same manner in the retina to elevate BDNF levels. The purpose of this study is to investigate the actions of SSRIs on serotonin physiology and BDNF signaling in the retina.

Methods: : Total RNA was isolated from human RPE and ARPE-19 cells. Reverse transcriptase (RT)-PCR for BDNF, 5-HT (serotonin) receptors and the 5-HT transporter was performed. ARPE-19 cells cultured in DMEM/F12 serum free media in 12-well plates were exposed to fluoxetine (10um) and serotonin (100um) at multiple time points. Expression of total BDNF mRNA was analyzed via real-time PCR and total secreted BDNF protein was quantified via ELISA.

Results: : RT-PCR using exon-spanning primers yielded products of the predicted size in RPE and ARPE-19 cells for 5-HT1a, 5-HT6, and 5-HT7 receptors, the 5-HT transporter and BDNF. The 5-HT2a receptor was only present on ARPE-19 cells. In cells exposed to fluoxetine and serotonin an increase in BDNF mRNA was observed after 48 hours and persisted up to one week while an increase in secreted BDNF protein was detected by day 12.

Conclusions: : Our initial experiments have demonstrated that RPE cells possess the molecular machinery to respond to the actions of SSRI’s and serotonin. Furthermore, our data may suggest that SSRI’s have therapeutic potential in treating retinal degenerations by increasing retinal BDNF levels.

Keywords: retina • gene/expression • drug toxicity/drug effects 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.